Please use this identifier to cite or link to this item:
Title: Azo dyes and the blood-brain barrier: Robert Aird's novel concept in chronic neurological disease (1903-2000).
Austin Authors: Bladin, Peter F 
Affiliation: Comprehensive Epilepsy Program, Austin Health, Heidelberg, Victoria, Australia
Issue Date: 29-Aug-2013
Publication information: Journal of Clinical Neuroscience 2013; 21(1): 33-9
Abstract: The well-established medical involvement of derivatives of the azo dye industry lent credibility to the 1935 announcement by Stanley Cobb of the use of vital brilliant red dye as an anticonvulsant. Although in the fullness of time clinical experience would discard this concept, nevertheless it was to give rise to Robert Aird who posited that the mechanism of action of this dye was due to its ability to decrease the permeability of the blood-brain barrier. In a very prolonged exploration of this concept, Aird concluded that blood-brain barrier permeability underlay the causation of a long list of chronic neurological conditions--a concept that was eventually abandoned. This article examines the details and the effects of this concept and its impact upon neurology.
Gov't Doc #: 24238829
DOI: 10.1016/j.jocn.2013.06.014
Journal: Journal of Clinical Neuroscience
Type: Journal Article
Subjects: Anticonvulsants
Azo dyes
Blood–brain barrier
Chronic neurological condition
Azo Compounds.history.pharmacology
Blood-Brain Barrier.drug effects
Coloring Agents.history.pharmacology
Epilepsy.drug therapy.etiology.physiopathology
History, 20th Century
History, 21st Century
United States
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Feb 6, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.